Collectively, these results provide further support for the idea that axon guidance genes, particularly those belonging to the SEMA signaling pathway, are putative tumor suppressors in Group 3 and Group 4 MB and that SEMA4D is a novel prognostic indicator specifically in Group 4. This evidence concerns the gene SEMA4D and neoplasm.